1,493
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression

, , , , , , , & ORCID Icon show all
Pages 1964-1975 | Received 05 Mar 2021, Accepted 27 Apr 2021, Published online: 23 May 2021

References

  • Jain M, Zhang L, He M, et al. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013;20(3):361–370.
  • Terzolo M, Ardito A, Zaggia B, et al. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine. 2012;42(3):521–525.
  • Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282–326.
  • Rubin B, Pilon C, Pezzani R, et al. The effects of mitotane and 1alpha,25-dihydroxyvitamin D3 on Wnt/beta-catenin signaling in human adrenocortical carcinoma cells. J Endocrinol Invest. 2020;43(3):357–367.
  • DiStefano JK, Davis B. Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019;11(4):112019.
  • Namba R, Kaneko H, Suzumura A, et al. In vitro epiretinal membrane model and antibody permeability: relationship with anti-VEGF resistance in diabetic macular edema. Invest Ophthalmol Vis Sci. 2019;60(8):2942–2949.
  • He YC, Shen Y, Cao Y, et al. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker. Cancer Biomarkers. 2016;16(1):127–135.
  • Liu W, Song J, Du X, et al. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model. Acta Biomater. 2019;91:195–208.
  • Yao Y, Wang X, Zhou D, et al. Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway. Aging (Albany NY). 2020;12(13):13059–13075.
  • Yan W, Liu S, Xu E, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene. 2013;32(5):599–609.
  • Wang H, Wei H, Wang J, et al. MicroRNA-181d-5p-containing exosomes derived from CAFs promote EMT by regulating CDX2/HOXA5 in breast cancer. molecular therapy. Nucleic acids. 2020;19: 654–667.
  • Ordóñez-Morán P, Dafflon C, Imajo M, et al. HOXA5 counteracts stem cell traits by inhibiting wnt signaling in colorectal cancer. Cancer Cell. 2015;28(6):815–829.
  • Gendronneau G, Lemieux M, Morneau M, et al. Influence of Hoxa5 on p53 tumorigenic outcome in mice. Am J Pathol. 2010;176(2):995–1005.
  • Chang CJ, Chen YL, Hsieh CH, et al. HOXA5 and p53 cooperate to suppress lung cancer cell invasion and serve as good prognostic factors in non-small cell lung cancer. J Cancer. 2017;8(6):1071–1081.
  • Aji G, Li F, Chen J, et al. Upregulation of PCP4 in human aldosterone-producing adenomas fosters human adrenocortical tumor cell growth via AKT and AMPK pathway. Int J Clin Exp Pathol. 2018;11(3):1197–1207.
  • Savard S, Amar L, Plouin PF, et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331–336.
  • Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–4833.
  • Chou CH, Chen YH, Hung CS, et al. Aldosterone impairs vascular smooth muscle function: from clinical to bench research. J Clin Endocrinol Metab. 2015;100(11):4339–4347.
  • Zennaro MC, Fernandes-Rosa F, Boulkroun S, et al. Bilateral idiopathic adrenal hyperplasia: genetics and beyond. Horm Metab Res. 2015;47(13):947–952.
  • Jouinot A, Armignacco R, Assie G. Genomics of benign adrenocortical tumors. J Steroid Biochem Mol Biol. 2019;193:105414.
  • Kim EM, Jung CH, Kim J, et al. The p53/p21 complex regulates cancer cell invasion and apoptosis by targeting Bcl-2 family proteins. Cancer Res. 2017;77(11):3092–3100.
  • Ohashi T, Idogawa M, Sasaki Y, et al. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res. 2013;11(12):1554–1563.